Business
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers","length":109,"tagName":"p","attribs":{}},{"type":"text","content":"Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.","length":362,"tagName":"p"},{"type":"image","alt":"Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.)","displaySize":"","headline":null,"caption":"Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":174,"url":"https://media.zenfs.com/en/prnewswire.com/9f2e91a2cde0080fbb40e564b19729d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pOy4uw26dtFTfjl0AvNW6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9f2e91a2cde0080fbb40e564b19729d2","width":400,"height":174}},"href":"https://mma.prnewswire.com/media/2687646/Oncolytics_Biotech_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Pelareorep continues to build clinical momentum, delivering encouraging results in challenging cancer types and has the potential to extend and improve the lives of patients," said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO. "We remain focused on optimizing the development pathway for pelareorep. Importantly, pelareorep has demonstrated a meaningful clinical benefit in two randomized phase 2 breast cancer studies, in multiple pancreatic c...